Cannabis and Multiple Sclerosis Spasticity

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Not medical advice

This article is educational, not medical advice. Multiple sclerosis is a serious neurological disease. Decisions about treatment—including whether to try cannabis-based medicines, which product, what dose, and how it interacts with your other MS drugs—must be made with a neurologist or MS specialist. Cannabis can interact with immunomodulators and other drugs, affect cognition (already a concern in MS), and worsen balance and falls. Do not substitute cannabis for disease-modifying therapy or established antispastics without medical guidance.

Plain-language summary

Spasticity—involuntary muscle stiffness and spasms—affects roughly 60–80% of people with MS and is often poorly controlled by first-line drugs like baclofen and tizanidine Strong evidence ^[1].

Nabiximols (brand name Sativex, a 1:1 THC:CBD oromucosal spray) has been tested in large randomized controlled trials as add-on therapy for patients whose spasticity does not respond adequately to standard treatment. The pattern across studies is consistent: about 30–40% of patients report a clinically meaningful reduction (≥30% improvement on a 0–10 self-rated spasticity scale) Strong evidence ^[2][3][4]. Spasm frequency and sleep also improve modestly.

Objectively measured spasticity (using the Ashworth scale, which clinicians perform) shows little to no change Disputed ^[5]. This gap between "feels better" and "measures better" is real and matters for interpretation. Most clinical experts interpret patient-reported improvement as genuine symptom relief that objective scales fail to capture, rather than placebo, though the gap remains conceptually important.

What probably works

Nabiximols (Sativex) as add-on therapy for resistant spasticity. This is the best-evidenced cannabis use case in neurology. Pooled analyses of randomized controlled trials show approximately a 1-point reduction on the 0–10 patient-rated numerical rating scale for spasticity versus placebo, with responder rates (≥30% improvement) around 30–40% among patients who did not respond adequately to standard antispastics Strong evidence ^[2][3][4].

The American Academy of Neurology's 2014 systematic review concluded that nabiximols is "probably effective" for reducing patient-reported spasticity in MS, assigning it a Level B recommendation (moderate evidence) Strong evidence ^[6].

Spasm frequency also drops modestly in trials, with reductions of roughly 20–30% versus placebo Strong evidence ^[3][4].

Sleep quality improves, often as a secondary benefit of reduced nocturnal spasms Strong evidence ^[3][4].

The evidence base rests on four to five large, adequately blinded, randomized controlled trials conducted between 2003 and 2011. Responder-enriched designs (continuing only patients showing early benefit) are now standard, which means modern prescribing guidance advises stopping treatment if no meaningful improvement occurs within the first 4 weeks ^[4][10].

What might work

MS-related central neuropathic pain. The AAN review and one dedicated trial suggest potential benefit for pain in MS, but evidence is limited Weak / limited ^[6][7]. Most data come from non-MS neuropathic pain populations; MS-specific pain trials are few and have mixed results.

Bladder overactivity. Nabiximols reduced urinary urgency and incontinence episodes in one small randomized trial, but results have not been consistently replicated and sample sizes remain modest Weak / limited ^[8].

Inhaled or smoked cannabis. One small crossover trial in 30 MS patients showed patient-reported reductions in spasticity and pain but also significant acute cognitive impairment Weak / limited ^[9]. Real-world inhaled use is widespread, but high-quality, blinded comparative trials of smoked flower versus oromucosal spray or placebo are absent.

Oral THC (dronabinol) and oral cannabis extract (not nabiximols). The large CAMS trial (600+ patients) found no improvement in clinician-measured (Ashworth) spasticity but did find patient-reported benefit Disputed ^[5]. This outcome mirrors the gap seen in nabiximols trials. Follow-up observational data hinted at sustained long-term effects, but those were open-label and uncontrolled Weak / limited.

What does not work—or has no good evidence

MS tremor. Multiple trials have not shown meaningful benefit of cannabinoids for action or intention tremor in MS Strong evidence ^[6].

Disease modification (slowing MS progression, reducing relapses, or changing MRI lesion burden). No credible human evidence exists that cannabis or any cannabinoid modifies the underlying disease course No data. Animal models of experimental autoimmune encephalomyelitis have demonstrated immunomodulatory effects from some cannabinoids, but these have not translated into clinical disease-modifying outcomes in humans No data.

CBD-only products for spasticity. No good evidence supports the use of isolated CBD (without THC) for MS spasticity at typical consumer supplement doses No data. Marketing claims routinely assert CBD benefits for spasticity, but controlled trials supporting this are absent.

Strain-based predictions ("indica for spasticity"). The commercial cannabis classification of indica versus sativa strains does not reliably predict clinical effects and is largely a retail taxonomy with weak biological basis. Cannabinoid and terpene content—not plant morphology—drive effects. See cannabis pharmacology explainer for why this distinction is marketing folklore, not medicine.

What we don't know

• Optimal THC:CBD ratio. Whether other ratios (e.g., 1:2, 2:1, full-spectrum) outperform the 1:1 nabiximols formulation has not been directly tested in MS.
• Long-term sustainability. Whether benefit is sustained beyond 12 months or whether tolerance develops is unclear. Open-label extension trials suggest durability, but open-label data are vulnerable to bias Weak / limited ^[4].
• Bioequivalence of delivery methods. Whether inhaled cannabis is non-inferior to oromucosal spray at equivalent cannabinoid doses has not been studied head-to-head in MS.
• Optimal dosing in cognitive impairment. No guidance exists for patients with significant MS-related cognitive impairment, where THC's cognitive side effects are most problematic.
• Minor cannabinoids (CBG, THCV, etc.). Any clinical role in MS spasticity; current data are preclinical only No data.
• Falls and fracture risk. Whether cannabis use affects fall rates or bone fracture risk in ambulatory MS patients, who already face elevated risk, has not been systematically studied.
• Immunomodulatory effects in vivo. Whether cannabis or nabiximols affect MS relapse rates, disability progression, or MRI lesion burden via immunomodulation remains unknown No data.

Comparison with standard treatments

First-line antispastics in MS include oral baclofen, tizanidine, gabapentin, and benzodiazepines. All have established efficacy for reducing spasticity; all carry side effects including sedation, weakness, dry mouth, and in the case of tizanidine, hepatotoxicity requiring liver monitoring ^[1][10].

Nabiximols is positioned as add-on therapy only when first-line agents fail, are not tolerated, or produce inadequate relief—not as a first-line replacement ^[10]. Head-to-head randomized trials comparing nabiximols directly to baclofen, tizanidine, or gabapentin do not exist. In clinical practice, nabiximols is reserved for patients who have already tried and either failed or declined standard agents.

Botulinum toxin remains the standard of care for focal, regional spasticity (e.g., adductors, hamstrings). Intrathecal baclofen (via pump) is the most effective intervention for severe, generalized spasticity and is not replaced by cannabis-based medicines. Nabiximols fills a niche for patients with mild-to-moderate, multifocal spasticity that is inadequately controlled by oral agents.

Risks and side effects

Common adverse effects of nabiximols in MS trials: dizziness, fatigue, nausea, dry mouth, somnolence, and application-site discomfort. Discontinuation rates for adverse events run roughly 5–10% higher on active nabiximols versus placebo ^[2][3].

MS-specific concerns:

Cognition. MS itself impairs processing speed, memory, and attention in many patients. THC induces acute cognitive slowing and memory impairment, which compounds pre-existing deficits Strong evidence ^[9]. For cognitively preserved patients, the additional burden may be tolerable; for those already significantly impaired, it may not be.

Balance and falls. Dizziness and altered proprioception from THC compound existing gait impairment and cerebellar dysfunction. Falls are a major cause of injury and hospitalization in MS; cannabis use warrants careful fall-risk assessment.

Mood and anxiety. Anxiety and depression are common in MS. THC can worsen anxiety, especially at higher doses Strong evidence; low-dose benefit for anxiety has not been established in MS populations.

Psychosis risk. Personal or family history of psychotic illness is a contraindication Strong evidence.

Drug interactions. CBD inhibits several CYP450 enzymes (particularly CYP3A4) and can raise levels of co-administered drugs. This is less critical for most MS disease-modifying therapies but is relevant for clobazam, warfarin, and tacrolimus. See Cannabis and Polypharmacy Risks for detailed guidance ^[11].

Driving. THC impairs driving ability and reaction time. Nabiximols prescribing information advises against driving or operating machinery while dosing up and ongoing; this affects quality of life for working-age MS patients.

Immunomodulation in the context of MS DMTs. Theoretical concern exists that CBD or THC might interfere with disease-modifying immunotherapy, though no clinical evidence of harmful interactions has been documented No data.

Sources

How this page was made

Related

• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
• Cannabis and Psychosis Risk — THC raises psychosis risk in a dose-dependent manner, particularly in vulnerable groups.
• Cannabis Pharmacokinetics: How Cannabinoids Move Through the Body — What happens to THC and CBD once they enter your body, route by route.
• THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...